Expression and Prognostic Value of Tumor-Infiltrating Lymphocytes and PD-L1 in Hepatocellular Carcinoma

Figures & data

Table 1 Distribution Proportion of Main Anti-Tumor Effector Cells and PD-L1 in Hepatocellular Carcinoma and Paracancerous Tissues

	Cancer	Adjacent to Cancer	P
CD3^+	4.53 (2.06,10.50)	3.14 (1.89,5.59)	0.026
CD8^+/CD3^+	51.30 (32.80,62.10)	66.20 (56.45,71.50)	<0.001
CD4^+/CD3^+	45.10 (33.70, 61.05)	24.00 (20.00,30.70)	<0.001
CD4^+/CD8^+	0.88 (0.53,1.86)	0.36 (0.28,0.53)	<0.001
PD-L1	9.18 (4.91,15.85)	6.46 (2.90, 9.90)	0.01

Figure 1 Flow diagram of tumor infiltrating lymphocytes and PD-L1 in hepatocellular carcinoma. (A) Removal of adhesion of cells by forward angular scattering of FSC-An and FSH-H. (B) CD3 sets up a door to circle out CD3+T cells. (C) Elimination of dead cells by setting a gate through 7AAD. (D and E) Set up a gate to circle the CD4+ cells and CD8+ cells in CD3+T cells. (F and G) Through the control tube of the same type, the PD-L1 positive group was circled.

Figure 2 Flow diagram of tumor infiltrating lymphocytes and PD-L1 in paracancerous tissues. (A) Removal of adhesion of cells by forward angular scattering of FSC-An and FSH-H. (B) CD3 sets up a door to circle out CD3+T cells. (C) Elimination of dead cells by setting a gate through 7AAD. (D and E) Set up a gate to circle the CD4+ cells and CD8+ cells in CD3+T cells. (F and G) Through the control tube of the same type, the PD-L1 positive group was circled.

Table 2 Relationship Between the Expression of CD8/CD3 and PD-L1 in Hepatocellular Carcinoma and Clinicopathological Factors

Characteristics	Cases	CD8/CD3	t	P	PD-L1	t	P
Age (years)			0.266	0.791		0.769	0.444
<60	51	49.2±27.90			11.39±8.99
≥60	21	48.03±14.32			13.40±12.47
Gender			0.934	0.354		0.585	0.561
Male	51	47.66±17.63			12.42±10.82
Female	21	51.75±14.77			10.89±8.15
Tumor size (cm)			3.231	0.002		1.211	0.230
<5	23	57.65±14.85			14.07±10.48
≥5	49	44.73±16.25			10.99±9.85
Differentiation			0.649	0.519		0.045	0.964
High and medium	46	48.14±17.27			11.95±10.52
Low	26	51.18±15.65			12.07±8.82
TNM stage			2.493	0.015		2.229	0.029
I, II	37	53.50±15.95			9.47±6.67
III, IV	35	43.95±16.57			14.63±12.29
Cirrhosis			0.420	0.676		1.689	0.096
No	12	50.73±17.65			7.54±2.77
Yes	60	48.48±16.81			12.86±10.77
AFP (μg/L)			0.857	0.394		0.178	0.860
<20	15	45.53±17.92			11.56±10.25
≥20	57	49.73±16.60			12.08±10.13

Table 3 Univariate and Multivariate Cox Regression Analysis of Postoperative Prognosis in 72 Patients with Hepatocellular Carcinoma

Variable	Univariate Analysis		Multifactor Analysis
	HR(95% CI)	P	HR(95% CI)	P
Age (years)	0.538 (0.208~1.387)	0.200
Gender(Male/Female)	1.132 (0.520~2.464)	0.755
Tumor size (cm)	0.510 (0.230~1.132)	0.098
Differentiation(High and medium/Low	5.152 (2.393~11.095)	<0.001	4.720 (1.962~11.355)	<0.001
TNM stage(I II/III IV)	3.539 (1.667~7.514)	0.001
Cirrhosis (Yes/No)	1.372 (0.487~3.869)	0.549
AFP (μg/L)	2.064 (0.747~5.702)	0.162
CD8/CD3(Higher/Lower expression)	0.087 (0.036~0.212)	0.001	0.083 (0.032~0.211)	0.013
PD-L1 (Higher/Lower expression)	0.410 (0.192~0.876)	0.021	0.440 (0.202~0.959)	0.039

Figure 3 Kaplan–Meier survival analysis curve. (A) CD8/CD3; (B) PD-L1.